Brammer Bio, a viral vector contract development and manufacturing organization (CDMO), has implemented a three-year, $200 million investment program at its Alachua, FL facilities, that will establish more than 30 suites for clinical and commercial viral vector supply for a broad pipeline of gene therapies and gene-modified cell therapies.   “Brammer’s vision is to enable innovators to bring these advanced medicines to patients. We are committed to continuing our investment in our world-class ...